Mirum Pharmaceuticals Q3 net product sales surge, outlook raised

Overview

• US rare disease drugmaker's Q3 net product sales rose yr/yr to $185.7 mln

• Company posted Q3 net loss of $40.77 mln amid higher operating expenses

• Full-year 2026 net product sales guidance raised to $715 mln-$720 mln

Outlook

• Mirum raises 2026 net product sales guidance to $715 mln-$720 mln

Result Drivers

• LIVMARLI SALES GROWTH - Co said Q3 LIVMARLI net product sales rose 45% yr/yr, driven by expansion into additional rare cholestatic liver diseases

• BILE ACID MEDICINES - Q3 Bile Acid Medicines net product sales grew 28% yr/yr, reflecting increased demand for CHOLBAM and CTEXLI

• ATEBRIOZ APPROVAL AND LAUNCH - Co received US FDA approval and launched ATEBRIOZ for FOP, contributing to commercial momentum

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Mirum Pharmaceuticals, Inc. is $153.00, about 78.4% above its November 2 closing price of $85.74

Reuters Recommended Reads

• Nov 3 - Rhythm Pharma Q3 net loss narrower than estimated on IMCIVREE demand

• Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth

• Nov 2 - Tempus AI Q3 revenue slightly beats estimates; raises guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)